title: Malignant melanoma in teenagers and young adults.
abstract: BACKGROUND
  This study compares the natural history and treatment outcomes of cutaneous melanoma in teenagers and young adults to determine if exclusion of teenagers from investigative trials is justified.
  
  
  METHODS
  This is a chart review of patients between the ages of 13 and 40 years treated at The University of Texas MD Anderson Cancer Center for melanoma. Data related to the natural history and treatment outcomes were collected. Statistical tools were used to compare characteristics between teenagers and young adults. Cox proportional hazard models were utilized to examine the association between age group and overall survival.
  
  
  RESULTS
  Of the 476 patients, 109 were teenagers and 367 were young adults. Both groups had comparable disease stage, pathology, and rates of metastasis. Initial disease stage and pathology significantly influenced survival. Sixty-six of 452 patients with skin melanoma developed metastasis. Teenagers survived better than young adults from diagnosis of the skin primary and after development of systemic metastasis. Teenagers tolerated and benefited from interleukin-2-based systemic therapy and targeted therapies as well as the young adults.
  
  
  CONCLUSIONS
  Because of the similarities in natural history and treatment outcomes between teenage and young adult patients, it is recommended that teenage patients be officially enrolled on adult melanoma therapeutic trials.
authors.affiliation: Departments of *Melanoma Medical Oncology †Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Nathalie A
authors.initials: NA
authors.lastname: Kolandijan
authors.forename: Caimiao
authors.initials: C
authors.lastname: Wei
authors.forename: Anahit
authors.initials: A
authors.lastname: Burke
authors.forename: Agop Y
authors.initials: AY
authors.lastname: Bedikian
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016208:Databases, Factual; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007376:Interleukin-2